{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:51:15Z","timestamp":1791697875579,"version":"4.3.4"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"Importance<\/jats:title>Metabolic surgery leads to weight loss and improved health, but these outcomes are highly variable. Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1).<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy and safety of the GLP-1 receptor agonist, liraglutide, 3.0 mg, on percentage body weight reduction in patients with poor weight loss and suboptimal GLP-1 response after metabolic surgery.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Evaluation of Liraglutide 3.0 mg in Patients With Poor Weight Loss and a Suboptimal Glucagon-Like Peptide-1 Response (BARI-OPTIMISE) randomized placebo-controlled trial recruited adult patients at least 1 year after metabolic surgery who had experienced 20% or less body weight loss from the day of surgery and a suboptimal nutrient-stimulated GLP-1 response from 2 hospitals in London, United Kingdom, between October 2018 and November 2019. Key exclusion criteria were type 1 diabetes; severe concomitant psychiatric, gastrointestinal, cardiac, kidney or metabolic disease; and use of insulin, GLP-1 receptor analogues, and medication that can affect weight. The study period was 24 weeks followed by a 4-week follow-up period. Last participant follow-up was completed in June 2020. All participants and clinical study personnel were blinded to treatment allocation. Of 154 assessed for eligibility, 70 met trial criteria and were included in the study, and 57 completed follow-up.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Liraglutide, 3.0 mg, once daily or placebo as an adjunct to lifestyle intervention with a 500-kcal daily energy deficit for 24 weeks, on a 1:1 allocation by computer-generated randomization sequence, stratified by surgery type (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]) and type 2 diabetes status.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The primary outcome was change in percentage body weight from baseline to the end of the 24-week study period based on an intention-to-treat analysis. Participant safety was assessed through monitoring of biochemical parameters, including kidney and liver function, physical examination, and assessment for adverse events.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 70 participants (mean [SD] age, 47.6 [10.7] years; 52 [74%] female) with a poor weight loss response following RYGB or SG were randomized to receive 3.0-mg liraglutide (n\u2009=\u200935) or placebo (n\u2009=\u200935). All participants received at least 1 dose of the trial drug. Eight participants discontinued treatment (4 per group), and 2 in the 3.0-mg liraglutide group and 1 in the placebo group were lost to follow-up. Due to COVID-19 restrictions, 3 participants in the 3.0-mg liraglutide group and 7 in the placebo group were unable to attend their final in-person assessment. Estimated change in mean (SD) percentage body weight from baseline to week 24 was \u22128.82 (4.94) with liraglutide, 3.0 mg (n\u2009=\u200931), vs \u22120.54 (3.32) with placebo (n\u2009=\u200926). The mean difference in percentage body weight change for liraglutide, 3.0 mg, vs placebo was \u22128.03 (95% CI, \u221210.39 to \u22125.66; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Adverse events, predominantly gastrointestinal, were more frequent with liraglutide, 3.0 mg (28 events [80%]), than placebo (20 events [57%]). There were no serious adverse events and no treatment-related deaths.<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>These findings support the use of adjuvant liraglutide, 3.0 mg, for weight management in patients with poor weight loss and suboptimal GLP-1 response after metabolic surgery.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03341429<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2023.2930","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:29:42Z","timestamp":1690392582000},"page":"1003","source":"Crossref","is-referenced-by-count":181,"title":["Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery"],"prefix":"10.1001","volume":"158","author":[{"given":"Jessica","family":"Mok","sequence":"first","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam O.","family":"Adeleke","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac G.","family":"Magee","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Firman","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christwishes","family":"Makahamadze","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich C.","family":"Jassil","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastou","family":"Marvasti","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisia","family":"Carnemolla","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Devalia","sequence":"additional","affiliation":[{"name":"Bariatric Surgery Department Homerton University Hospital National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Fakih","sequence":"additional","affiliation":[{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elkalaawy","sequence":"additional","affiliation":[{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pucci","sequence":"additional","affiliation":[{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Adamo","sequence":"additional","affiliation":[{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana Z.","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Batterham","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Makaronidis","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom"},{"name":"Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"soi230046r1","first-page":"1997","article-title":"Bariatric surgery or intensive medical therapy for diabetes after 5 years.","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"issue":"10287","key":"soi230046r2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174?772 participants.","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"soi230046r3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","article-title":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.","volume":"43","author":"van Veldhuisen","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"soi230046r4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jama.2017.20897","article-title":"Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial.","volume":"319","author":"Peterli","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"soi230046r5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s00464-014-3829-7","article-title":"Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass.","volume":"29","author":"Manning","year":"2015","journal-title":"Surg Endosc"},{"issue":"3","key":"soi230046r6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/dme.2018.35.issue-3","article-title":"Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores.","volume":"35","author":"Pucci","year":"2018","journal-title":"Diabet Med"},{"issue":"2","key":"soi230046r7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13679-021-00425-1","article-title":"Use of weight loss medications in patients after bariatric surgery.","volume":"10","author":"Redmond","year":"2021","journal-title":"Curr Obes Rep"},{"issue":"3","key":"soi230046r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046407","article-title":"Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study.","volume":"11","author":"Brissman","year":"2021","journal-title":"BMJ Open"},{"issue":"12","key":"soi230046r9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","article-title":"Weight and metabolic outcomes 12 years after gastric bypass.","volume":"377","author":"Adams","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"soi230046r10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/nu13030762","article-title":"Do gut hormones contribute to weight loss and glycaemic outcomes after bariatric surgery?","volume":"13","author":"Papamargaritis","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"soi230046r11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/SLA.0b013e3180caa3e3","article-title":"Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.","volume":"246","author":"le Roux","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"soi230046r12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11695-013-1066-0","article-title":"Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans.","volume":"24","author":"Yousseif","year":"2014","journal-title":"Obes Surg"},{"issue":"7","key":"soi230046r13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"soi230046r14","doi-asserted-by":"publisher","DOI":"10.1111\/cob.2019.9.issue-4","article-title":"Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.","volume":"9","author":"Wharton","year":"2019","journal-title":"Clin Obes"},{"issue":"6","key":"soi230046r15","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/dom.2019.21.issue-6","article-title":"Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients.","volume":"21","author":"Suliman","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"soi230046r16","doi-asserted-by":"publisher","DOI":"10.1111\/cob.2019.9.issue-3","article-title":"Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version.","volume":"9","author":"Kolotkin","year":"2019","journal-title":"Clin Obes"},{"issue":"3","key":"soi230046r17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck depression inventories-IA and-II in psychiatric outpatients.","volume":"67","author":"Beck","year":"1996","journal-title":"J Pers Assess"},{"issue":"1","key":"soi230046r18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"soi230046r19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1080\/17512433.2022.2130760","article-title":"Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.","volume":"15","author":"Lin","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"soi230046r20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"soi230046r21","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"soi230046r22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial.","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"soi230046r23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11695-021-05884-y","article-title":"Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes.","volume":"32","author":"Elhag","year":"2022","journal-title":"Obes Surg"},{"issue":"2","key":"soi230046r24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"soi230046r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2807724\/jamasurgery_mok_2023_oi_230046_1696870070.90591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:18:57Z","timestamp":1697037537000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2807724"}},"subtitle":["The BARI-OPTIMISE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2023.2930","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}